These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36572925)

  • 1. The associations of total testosterone with probable nonalcoholic steatohepatitis and nonalcoholic fatty liver disease fibrotic progression in men with type 2 diabetes: a cross-sectional study.
    Zhang Z; Chen C; Wang Y; Wang N; Chen Y; Lu Y; Xia F
    Eur J Med Res; 2022 Dec; 27(1):307. PubMed ID: 36572925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes.
    Wang N; Wang Y; Zhang W; Chen Y; Chen X; Wang C; Li Q; Chen C; Jiang B; Lu Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3210. PubMed ID: 31351021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression.
    Wang Y; Lin Z; Wan H; Zhang W; Xia F; Chen Y; Chen X; Wang C; Chen C; Wang N; Lu Y
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e818-e823. PubMed ID: 34402473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of non-alcoholic fatty liver disease with total testosterone in non-overweight/obese men with type 2 diabetes mellitus.
    Yang LJ; Zhou JZ; Zheng YF; Hu X; He ZY; Du LJ; Gu X; Huang XY; Li J; Li YQ; Pan LY; Zhang XX; Gu XJ
    J Endocrinol Invest; 2023 Aug; 46(8):1565-1572. PubMed ID: 36725809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus.
    Lee H; Kim G; Choi YJ; Huh BW; Lee BW; Kang ES; Cha BS; Lee EJ; Lee YH; Huh KB
    Diabetes Metab J; 2020 Apr; 44(2):267-276. PubMed ID: 30877708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 7. Lower eGFR is associated with increased probability of liver fibrosis in Chinese diabetic patients.
    Wang Y; Yu Y; Wan H; Chen Y; Xia F; Zhang W; Zhang K; Gu X; Zhang Y; Lin Z; Yu Y; Wang N; Lu Y
    Diabetes Metab Res Rev; 2020 Jul; 36(5):e3294. PubMed ID: 32017389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients.
    Sun Y; Hong L; Huang Z; Wang L; Xiong Y; Zong S; Zhang R; Liu J; Zang S
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3661-e3669. PubMed ID: 35766414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD.
    Sarkar MA; Suzuki A; Abdelmalek MF; Yates KP; Wilson LA; Bass NM; Gill R; Cedars M; Terrault N;
    Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1267-1274.e1. PubMed ID: 33010412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study.
    Han WM; Apornpong T; Lwin HMS; Thammapiwan S; Boonrungsirisap J; Gatechompol S; Ubolyam S; Tangkijvanich P; Kerr SJ; Avihingsanon A
    Clin Infect Dis; 2023 Dec; 77(12):1687-1695. PubMed ID: 37477514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis.
    Méndez-Sánchez N; Cerda-Reyes E; Higuera-de-la-Tijera F; Salas-García AK; Cabrera-Palma S; Cabrera-Álvarez G; Cortez-Hernández C; Pérez-Arredondo LA; Purón-González E; Coronado-Alejandro E; Panduro A; Rodríguez-Hernández H; Cruz-Ramón VC; Valencia-Rodríguez A; Qi X; Hamdan-Pérez N; Aguilar-Olivos NE; Barranco-Fragoso B; Ramírez-Pérez O; Vera-Barajas A
    F1000Res; 2020; 9():56. PubMed ID: 32595949
    [No Abstract]   [Full Text] [Related]  

  • 12. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Amjad W; Shalaurova I; Garcia E; Gruppen EG; Dullaart RPF; DePaoli AM; Jiang ZG; Lai M; Connelly MA
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
    Chen K; Sng WK; Quah JH; Liu J; Chong BY; Lee HK; Wang XF; Tan NC; Chang PE; Tan HC; Bee YM; Goh GBB
    PLoS One; 2020; 15(8):e0236977. PubMed ID: 32822391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes.
    Wang N; Wang Y; Chen X; Zhang W; Chen Y; Xia F; Wan H; Li Q; Jiang B; Hu B; Lu Y
    Front Endocrinol (Lausanne); 2019; 10():926. PubMed ID: 32063885
    [No Abstract]   [Full Text] [Related]  

  • 18. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
    Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
    Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study.
    Mantovani A; Zusi C; Csermely A; Salvagno GL; Colecchia A; Lippi G; Maffeis C; Targher G
    Hormones (Athens); 2022 Sep; 21(3):477-486. PubMed ID: 35831700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
    Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
    Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.